|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shigeta K, Ishii Y, Hasegawa H, Okabayashi
K and Kitagawa Y: Evaluation of 5-fluorouracil metabolic enzymes as
predictors of response to adjuvant chemotherapy outcomes in
patients with stage II/III colorectal cancer: A decision-curve
analysis. World J Surg. 38:3248–3256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lindskog EB, Derwinger K, Gustavsson B,
Falk P and Wettergren Y: Thymidine phosphorylase expression is
associated with time to progression in patients with metastatic
colorectal cancer. BMC Clin Pathol doi. 14:252014. View Article : Google Scholar
|
|
6
|
Mayer RJ: Moving beyond fluorouracil for
colorectal cancer. N Engl J Med. 343:963–964. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JJ, Beumer JH and Chu E: Therapeutic
drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol.
78:447–464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maindrault-Goebel F, Louvet C, André T,
Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V,
Krulik M and de Gramont A: Oxaliplatin added to the simplified
bimonthly leucovorin and 5-fluorouracil regimen as second-line
therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J
Cancer. 35:1338–1342. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Quasar Collaborative Group, . Gray R,
Barnwell J, McConkey C, Hills RK, Williams NS and Kerr DJ: Adjuvant
chemotherapy versus observation in patients with colorectal cancer:
A randomized study. Lancet. 370:2020–2029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lembersky BC, Wieand HS, Petrelli NJ,
O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall
ME, Jacobs AD, et al: Oral uracil and tegafur plus leucovorin
compared with intravenous fluorouracil and leucovorin in stage II
and III carcinoma of the colon: Results from National Surgical
Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol.
24:2059–2064. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Labianca R, Nordlinger B, Beretta GD,
Brouquet A and Cervantes A: ESMO Guidelines Working Group: Primary
colon cancer: ESMO Clinical Practice Guidelines for diagnosis,
adjuvant treatment and follow-up. Ann Oncol. 21 Suppl 5:v70–v77.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deboever G, Hiltrop N, Cool M and
Lambrecht G: Alternative treatment options in colorectal cancer
patients with 5-fluorouracil- or capecitabine-induced
cardiotoxicity. Clin Colorectal Cancer. 12:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bronckaers A, Gago F, Balzarini J and
Liekens S: The dual role of thymidine phosphorylase in cancer
development and chemotherapy. Med Res Rev. 29:903–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Brien TS, Fox SB, Dickinson AJ, Turley
H, Westwood M, Moghaddam A, Gatter KC, Bicknell R and Harris AL:
Expression of the angiogenic factor thymidine
phosphorylase/platelet-derived endothelial cell growth factor in
primary bladder cancers. Cancer Res. 56:4799–4804. 1996.PubMed/NCBI
|
|
17
|
Miwa M, Ura M, Nishida M, Sawada N,
Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a
novel oral fluoropyrimidine carbamate, capecitabine, which
generates 5-fluorouracil selectively in tumours by enzymes
concentrated in human liver and cancer tissue. Eur J Cancer.
34:1274–1281. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takebayashi Y, Yamada K, Miyadera K,
Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y,
Akiyama S and Aikou T: The activity and expression of thymidine
phosphorylase in human solid tumours. Eur J Cancer. 32A:1227–1232.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nozawa T, Enomoto T, Koshida Y, Sato Y and
Kuranami M: Specific enhanced expression of platelet-derived
endothelial cell growth factor in submucosa of human colorectal
cancer. Dis Colon Rectum. 47:2093–2100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amatori F, Di Paolo A, Del Tacca M,
Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M and Danesi
R: Thymidylate synthase, dihydropyrimidine dehydrogenase and
thymidine phosphorylase expression in colorectal cancer and normal
mucosa in patients. Pharmacogenet Genomics. 16:809–816. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Bruin M, van Capel T, Van der Born K,
Kruyt FA, Fukushima M, Hoekman K, Pinedo HM and Peters GJ: Role of
platelet-derived endothelial cell growth factor/thymidine
phosphorylase in fluoropyrimidine sensitivity. Br J Cancer.
88:957–64. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees
VC, Turley H, Fox SB, Gatter KC, Harris AL and Bicknell R:
Thymidine phosphorylase is angiogenic and promotes tumor growth.
Proc Natl Acad Sci USA. 92:pp. 998–1002. 1995, View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takebayashi Y, Akiyama S, Akiba S, Yamada
K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T:
Clinicopathologic and prognostic significance of an angiogenic
factor, thymidine phosphorylase, in human colorectal carcinoma. J
Natl Cancer Inst. 88:1110–1117. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahn MJ, Choi JH, Oh HS, Lee YY, Kim IS,
Choi IY, Lee KH, Song KW and Park CK: Thymidylate synthase,
thymidine phosphorylase, VEGF and p53 protein expression in primary
colorectal cancer for predicting response to 5-fluorouracil-based
chemotherapy. Cancer Res Treat. 37:216–222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kataoka K, Kanazawa A, Nakajima A,
Yamaguchi A and Arimoto A: Prognostic value of biomarkers in
metastatic colorectal cancer patients. J Surg Res. 194:343–350.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petrioli R, Bargagli G, Lazzi S, Pascucci
A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI,
Lorenzi B, et al: Thymidine phosphorylase expression in metastatic
sites is predictive for response in patients with colorectal cancer
treated with continuous oral capecitabine and biweekly oxaliplatin.
Anticancer Drugs. 21:313–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamada H, Iinuma H and Watanabe T:
Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes'
stage B and C colorectal cancer patients treated with oral
5-fluorouracil-based adjuvant chemotherapy. Oncol Rep. 19:729–735.
2008.PubMed/NCBI
|
|
28
|
Jensen SA, Vainer B, Witton CJ, Jørgensen
JT and Sørensen JB: Prognostic significance of numeric aberrations
of genes for thymidylate synthase, thymidine phosphorylase and
dihydrofolate reductase in colorectal cancer. Acta Oncol.
47:1054–1061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meropol NJ, Gold PJ, Diasio RB, Andria M,
Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E and Schwarting
R: Thymidine phosphorylase expression is associated with response
to capecitabine plus irinotecan in patients with metastatic
colorectal cancer. J Clin Oncol. 24:4069–4077. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duffaud F and Therasse P: New guidelines
to evaluate the response to treatment in solid tumors. Bull Cancer.
87:881–886. 2000.(In French). PubMed/NCBI
|
|
33
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Egger M, Smith Davey G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ogawa M, Watanabe M, Mitsuyama Y, Anan T,
Ohkuma M, Kobayashi T, Eto K and Yanaga K: Thymidine phosphorylase
mRNA expression may be a predictor of response to post-operative
adjuvant chemotherapy with S-1 in patients with stage III
colorectal cancer. Oncol Lett. 8:2463–2468. 2014.PubMed/NCBI
|
|
36
|
Donada M, Bonin S, Nardon E, De Pellegrin
A, Decorti G and Stanta G: Thymidilate synthase expression predicts
longer survival in patients with stage II colon cancer treated with
5-flurouracil independently of microsatellite instability. J Cancer
Res Clin Oncol. 137:201–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yanagisawa Y, Maruta F, Iinuma N, Ishizone
S, Koide N, Nakayama J and Miyagawa S: Modified
Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and
predicting therapeutic efficacy by expression of tumor-related
enzymes. Scand J Gastroenterol. 42:477–484. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ichikawa W, Uetake H, Shirota Y, Yamada H,
Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both
gene expression for orotate phosphoribosyltransferase and its ratio
to dihydropyrimidine dehydrogenase influence outcome following
fluoropyrimidine-based chemotherapy for metastatic colorectal
cancer. Br J Cancer. 89:1486–1492. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tokunaga Y, Hosogi H, Hoppou T, Nakagami
M, Tokuka A and Ohsumi K: Prognostic value of thymidine
phosphorylase/platelet-derived endothelial cell growth factor in
advanced colorectal cancer after surgery: Evaluation with a new
monoclonal antibody. Surgery. 131:541–547. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Metzger R, Danenberg K, Leichman CG,
Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L
and Danenberg PV: High basal level gene expression of thymidine
phosphorylase (platelet-derived endothelial cell growth factor) in
colorectal tumors is associated with nonresponse to 5-fluorouracil.
Clin Cancer Res. 4:2371–2376. 1998.PubMed/NCBI
|
|
41
|
Soong R, Shah N, Salto-Tellez M, Tai BC,
Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, et al: Prognostic
significance of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase protein expression in
colorectal cancer patients treated with or without
5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI
|
|
45
|
Nishimura G, Terada I, Kobayashi T,
Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu
K, Ohta T and Miwa K: Thymidine phosphorylase and dihydropyrimidine
dehydrogenase levels in primary colorectal cancer show a
relationship to clinical effects of 5′-deoxy-5-fluorouridine as
adjuvant chemotherapy. Oncol Rep. 9:479–482. 2002.PubMed/NCBI
|
|
46
|
Matsuura T, Kuratate I, Teramachi K, Osaki
M, Fukuda Y and Ito H: Thymidine phosphorylase expression is
associated with both increase of intratumoral microvessels and
decrease of apoptosis in human colorectal carcinomas. Cancer Res.
59:5037–5040. 1999.PubMed/NCBI
|
|
47
|
Elamin YY, Rafee S, Osman NO, Byrne KJ and
Gately K: Thymidine phosphorylase in cancer; enemy or friend?
Cancer Microenviron. 9:33–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bijnsdorp IV, Azijli K, Jansen EE,
Wamelink MM, Jakobs C, Struys EA, Fukushima M, Kruyt FA and Peters
GJ: Accumulation of thymidine-derived sugars in thymidine
phosphorylase overexpressing cells. Biochem Pharmacol. 80:786–792.
2010. View Article : Google Scholar : PubMed/NCBI
|
